» Articles » PMID: 17943424

Living at Risk: Concealing Risk and Preserving Hope in Huntington Disease

Overview
Journal J Genet Couns
Publisher Wiley
Specialty Genetics
Date 2007 Oct 19
PMID 17943424
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Much of the qualitative research on Huntington disease has focused on the genetic testing aspects of HD. The overall purpose of this qualitative study was to gather information about the everyday experience of living with the risk of developing Huntington disease in a sample of individuals at risk for HD who have chosen not to pursue genetic testing. Data for this article was obtained from unstructured, open-ended qualitative interviews of a sample of people participating in the PHAROS study. PHAROS, the Prospective Huntington At-Risk Observational Study, is a multi-site study that aims to establish whether experienced clinicians can reliably determine the earliest clinical symptoms of Huntington disease in individuals at 50% risk for HD who have chosen not to undergo genetic testing. Interviews were conducted at six PHAROS research sites across the United States. In this paper, the research team used qualitative description to construct and explore two main themes: (1) careful concealment of risk as an act of self-preservation and (2) preserving hope.

Citing Articles

Predictive genetic testing for Huntington's disease: Exploring participant experiences of uncertainty and ambivalence between clinic appointments.

Ballard L, Doheny S, Dimond R, Lucassen A, Clarke A J Genet Couns. 2024; 34(1):e1911.

PMID: 38741209 PMC: 11735177. DOI: 10.1002/jgc4.1911.


Experiences of predictive genetic testing in inherited motor neuron disease: Findings from a qualitative interview study.

Howard J, Forrest Keenan K, Mazanderani F, Turner M, Locock L J Genet Couns. 2024; 34(1):e1904.

PMID: 38628040 PMC: 11735176. DOI: 10.1002/jgc4.1904.


Fluctuating salience in those living with genetic risk of motor neuron disease: A qualitative interview study.

Howard J, Mazanderani F, Forrest Keenan K, Turner M, Locock L Health Expect. 2024; 27(2):e14024.

PMID: 38528673 PMC: 10963887. DOI: 10.1111/hex.14024.


A pilot evaluation of an 8-week mindfulness-based stress reduction program for people with pre-symptomatic Huntington's disease.

Velissaris S, Davis M, Fisher F, Gluyas C, Stout J J Community Genet. 2023; 14(4):395-405.

PMID: 37458974 PMC: 10444936. DOI: 10.1007/s12687-023-00651-1.


Using a Clinical Formulation to Understand Psychological Distress in People Affected by Huntington's Disease: A Descriptive, Evidence-Based Model.

Dale M, Wood A, Zarotti N, Eccles F, Gunn S, Kiani R J Pers Med. 2022; 12(8).

PMID: 35893316 PMC: 9332789. DOI: 10.3390/jpm12081222.


References
1.
Gusella J, Wexler N, Conneally P, Naylor S, Anderson M, Tanzi R . A polymorphic DNA marker genetically linked to Huntington's disease. Nature. 1983; 306(5940):234-8. DOI: 10.1038/306234a0. View

2.
Forrest K, Simpson S, Wilson B, van Teijlingen E, McKee L, Haites N . To tell or not to tell: barriers and facilitators in family communication about genetic risk. Clin Genet. 2003; 64(4):317-26. DOI: 10.1034/j.1399-0004.2003.00142.x. View

3.
Sandelowski M . Whatever happened to qualitative description?. Res Nurs Health. 2000; 23(4):334-40. DOI: 10.1002/1098-240x(200008)23:4<334::aid-nur9>3.0.co;2-g. View

4.
Creighton S, Almqvist E, MacGregor D, Fernandez B, Hogg H, Beis J . Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000. Clin Genet. 2003; 63(6):462-75. DOI: 10.1034/j.1399-0004.2003.00093.x. View

5.
Taylor S . Predictive genetic test decisions for Huntington's disease: elucidating the test/no-test dichotomy. J Health Psychol. 2005; 10(4):597-612. DOI: 10.1177/1359105305053442. View